Mesoblast Limited

ASX:MSB ISIN:AU000000MSB8

 Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients. 
 
     

View in Other Languages

News

Mesoblast Limited (ASX:MSB) Announces Strategic Expansion Of Clinical Programs In Bone And Cartilage Repair

🕔2/27/2008 10:01:03 AM 3499

Adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC: MBLTY), announced today that it was very well resourced to strategically expand its clinical programs in bone and cartilage repair, and to execute on its commercial objectives.

Read Full Article▸

Mesoblast Limited's (ASX:MSB) Bone Repair Trial Results Show Stem Cells Accelerate Fracture Healing

🕔2/13/2008 12:45:36 PM 4138

Australia's adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC:MBLTY), today announced highly successful results from its clinical trial at The Royal Melbourne Hospital in 10 patients suffering from non-healing, long bone fractures of the legs.

Read Full Article▸

MESOBLAST LIMITED Market Briefing - Mr Michael Spooner, Executive Chairman

🕔3/24/2006 10:30:00 AM 1828

MESOBLAST LIMITED Market Briefing - Mr Michael Spooner, Executive Chairman; Boardroomradio is pleased to announce that MESOBLAST LIMITED (ASX: MSB) has published an audio file. The following presentat

Read Full Article▸

Mesoblast and Cordis Corporation to Join Forces in Adult Stem Cell Heart Trial

🕔11/7/2005 1:05:10 PM 2176

Australian adult stem cell company, Mesoblast Limited (ASX:MSB), today announced that Cordis Corporation, a Johnson & Johnson company, will join forces in its upcoming adult stem cell Pilot Cardiac Clinical Trial through an agreement with Mesoblast's American affiliated company, Angioblast Systems Inc.

Read Full Article▸
###

211,901 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 217) (Last 30 Days: 1242) (Since Published: 69018) 

Company Data

    Headquarters
  • Level 39
    55 Collins Street
    Melbourne 3000
    AUSTRALIA
    • Telephone
  • +61-3-9639-6036 
    • Fax
  • +61-3-9369-6030 
    • Principal Sector
  • Health & Pharm 
    • Principal Industry
  • Biotechnology 
    • Listed
  • 2004/12/16 
    • Homepage
  • www.mesoblast.com

Company Reports

More News Results

  • 2024/07/23: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L*
  • 2024/07/22: Confirmatory Phase 3 Back Pain Trial Actively Enrols*
  • 2024/07/12: Appendix 3Y for Philip Krause*
  • 2024/07/12: Notification regarding unquoted securities - MSB*
  • 2024/07/12: Notification of cessation of securities - MSB*
  • 2024/07/12: Change in substantial holding*
  • 2024/07/09: Mesoblast Resubmits BLA with FDA for Ryoncil Approval*
  • 2024/07/01: Mesoblast to File BLA for Ryoncil FDA Approval Next Week*
  • 2024/06/03: Mesoblast Corporate Presentation at Investor Conference*
  • 2024/06/03: Corporate Presentation*
*refer to company website

Presentations

Download Presentation